RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 80
Summary
- Conditions
- Lymphoma
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a first-in-human, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors or lymphomas. The study will include 2 dosing periods: A Dose Escalatio...
This is a first-in-human, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors or lymphomas. The study will include 2 dosing periods: A Dose Escalation (Phase 1) followed by an Expansion (Phase 2).
Tracking Information
- NCT #
- NCT03815682
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Study Director: Daniel Vlock, MD Repertoire Immune Medicines
Get Well Soon